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Clinical Findings and Management of Diabetic Papillopathy:  
A Case Report
Abstract
Diabetic papillopathy is an uncommon ocular manifestation of diabetes 
that is associated with a rapid decrease in hemoglobin A1c. The typical pre-
sentation of this condition tends to be asymptomatic with normal intracra-
nial pressure. This case report describes a 64-year-old Caucasian male pre-
senting with diabetic papillopathy. Because this is a diagnosis of exclusion, 
magnetic resonance imaging, magnetic resonance venography, and lumbar 
puncture must be performed to rule out other possible causes of optic disc 
edema, including ischemia, infection, inflammation, infiltration, increased 
intracranial pressure from space-occupying lesions, and idiopathic intra-
cranial hypertension.
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INTRODUCTION
Diabetic papillopathy is an uncommon cause of optic disc swelling that oc-
curs in patients with diabetes mellitus (DM).1,2 Characteristic clinical fea-
tures are hyperemic optic disc edema with otherwise unremarkable diag-
nostic test results. The pathophysiology of diabetic papillopathy is unclear, 
but the literature suggests that a contributory factor is diabetic microvas-
cular changes causing fluid leakage into the optic nerve.1-5 This condition 
has also been associated with a rapid lowering of blood sugar.2,4,6 Diabetic 
papillopathy is considered a diagnosis of exclusion; therefore, diagnostic 
testing to rule out all other possible causes of optic disc edema should in-
clude cranial imaging for the detection of space-occupying lesions, lumbar 
puncture to determine intracranial pressure (ICP), and serological studies 
of the cerebral spinal fluid (CSF) to rule out infectious, infiltrative, and in-
flammatory causes.1,4,7 
Although diabetic papillopathy is a relatively benign, self-limiting condi-
tion with minimal visual impact, cases have shown that the use of intra-
vitreal bevacizumab injections may hasten resolution in individuals with 
significant visual reduction.8,9 
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CASE REPORT
A 64-year-old Caucasian male presented for his 1-month post-operative examination following cataract surgery of 
his left eye (OS). He reported no visual changes or concerns and was currently using 1% prednisolone acetate oph-
thalmic suspension once daily in his left, post-operative eye. The patient’s ocular history was significant for type 
II DM without ocular manifestations and cataract extraction with posterior chamber intraocular lens implants in 
both eyes (OU). The patient had a history of type II DM for 10 years, rheumatoid arthritis, hypothyroidism, and hy-
pertension. His medications included amlodipine, glipizide, levothyroxine, losartan, metformin, methotrexate, and 
saxagliptin. He was allergic to penicillin and lisinopril. His hemoglobin A1c (HbA1c) levels had decreased by 1.5% in 
the month of presentation compared to the level recorded 3 months previously (Table 1).
On examination, his best corrected visual acuities (BCVA) were 20/20-2 in the right eye (OD) and 20/30+2 in the 
left eye. BCVA OS was 20/25 prior to developing a visual significant cataract and undergoing cataract surgery. Pupils 
were equally round and reactive to light with no relative afferent pupillary defect. Extraocular movements and con-
frontation visual fields were full. Intraocular pressures with Goldmann applanation tonometry were 17mmHg OD 
and 15mmHg OS. Anterior segment of the eyes was unremarkable and he was pseudophakic in both eyes. 
Dilated fundus exam of the optic nerve revealed grade 4 disc edema OD with peripapillary hemorrhages 360° and 
grade 2 disc edema OS with a few hemorrhages (Figures 1,2), which were graded using the Modified Frisén Scale 
(Table 3). The posterior pole of the retina showed multiple scattered hemorrhages and vessel tortuosity OU. Spec-
tral domain optical coherence tomography (SD-OCT) of the retinal nerve fiber layer (RNFL) showed significant 
RNFL thickening, with a global value of 244 μm OD and 210 μm OS. SD-OCT of the macula was normal without 
macular edema OU.
The patient was diagnosed with bilateral optic disc edema and moderate non-proliferative diabetic retinopathy 
(NPDR) without macular edema, which was worse in the right eye, according to the Early Treatment for Diabetic 
Retinopathy Study (ETDRS). Due to these findings, a more detailed review of systems was conducted. He denied 
any headaches, nausea, ocular pain, malaise, or transient vision loss. There were no reports of vitamin A supple-
ment, corticosteroid, or recent tetracycline use. His blood pressure was 126/66 mmHg in an office setting. He was 
subsequently admitted to the emergency room for a neurological work up, including imaging, lumbar puncture 
(LP), and complete blood count (CBC), to determine the cause of the optic disc edema. 
Diagnostic Testing
Computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance venography (MRV) of 
the head showed no abnormalities to account for the optic nerve swelling. His neurological examination was also 
unremarkable. Lumbar puncture (LP) revealed an opening pressure of 16cm of H2O (normal range in adults 6-25cm 
of H2O) and unremarkable cerebral spinal fluid (CSF). CBC results were normal. These test results ruled out the 
possibility that his symptoms were due to any space-occupying lesions, infections, or an increase in intracranial 
pressure.
Follow up visits
At his follow-up visits, his BCVA remained stable. The amount of optic nerve edema decreased at each subsequent 
visit at 1 month and 3 months, and had resolved by the 5-month follow-up. Resolution of the optic disc edema re-
mained stable at his 7-month follow-up. Humphrey visual field 24-2 SITA (Swedish Interactive Testing Algorithm) 
Faster acquired on his 7-month follow-up showed scattered superior defects OD and scattered edge defects OS with 
good reliability; however, this was the patient’s first visual field test and a repeated test will be beneficial. Figures 
1-13 and Tables 2 and 4 demonstrate the continuous improvement in optic disc edema over the 7 months after initial 
presentation. 
After extensive testing to exclude any other possible etiologies, the final diagnosis was diabetic papillopathy. This is 
consistent with the patient’s lack of symptoms, moderate NPDR, and the rapid decrease in his HbA1c levels. By his 
5-month follow-up, the optic disc edema had resolved and remained stable at his 7-month follow-up. 
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*Last HbA1c before presentation
Table 2: Global RNFL over time 
Right Eye (μm) Left Eye (μm)
Initial Visit 244 210
1-month follow-up 165 131
3-month follow-up 118 112
5-month follow-up 98 101
7-month follow-up 101 98
Table 3: Modified Frisén Scale 
Modified Frisén Scale
Grade Characteristics 
0 – Normal Radial NFL without tortuosity
1 - Minimal
No elevation of borders
Obscuration of the nasal border of the disc
Disruption of normal radial NFL arrangement 
Normal temporal disc margin
2 – Low
Elevation of nasal border
Obscuration of all borders 
Peripapillary halo
No major vessel obscuration
3 - 
Moderate
Elevation of all borders
Obscuration of all borders 
Peripapillary halo 
Obscuration of one or more segment of a major blood vessel leaving the disc 
4 - Marked
Elevation of entire optic nerve head
Obscuration of all borders
Peripapillary halo
Total obscuration of a major blood vessel on the disc
5 – Severe Total obscuration of a major blood vessel on disc and partial obscuration of all vessel on disc
Table 4: Grade of optic disc edema based on the Modified Frisén Score over time
Right Eye Left Eye
Initial Visit 4 2
1-month follow-up 2 1
3-month follow-up 1 1
5-month follow-up 0 0
7-month follow-up 0 0
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Figures 1-8: Fundus photographs
Figure 1: Initial visit, right eye
Figure 4: 1-month follow-up, left eye
Figure 7: 7-month follow up, right eye
Figure 2: Initial visit, left eye
Figure 5: 5-month follow up, right eye
Figure 8: 7-month follow up, left eye
Figure 3: 1-month follow-up, right eye
Figure 6: 5-month follow up, left eye
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Figure 9: Spectralis SD-OCT at the initial visit, right eye
Figure 10: Spectralis SD-OCT at the initial visit, left eye
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Figure 11: Spectralis SD-OCT at the 7-month follow up
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Figure 12: Humphrey Visual Field 24-2 SITA Faster at the 7-month follow-up
DISCUSSION
Diabetic papillopathy is a rare cause of optic disc edema that is seen in 1.4% of diabetic patients; it is considered 
a diagnosis of exclusion.1,2,10 The condition may affect patients with either type I or II DM without any age, race, 
or gender predilection, and is often underdiagnosed due to its largely asymptomatic, transient nature.1,2 Patients 
affected with this condition generally have minimal to no visual disturbances or visual field loss, and an afferent 
pupillary defect is typically not present.3 Visual acuities may be affected in cases with concurrent macular edema, 
and a typical visual field defect is an enlarged blind spot. 
Diabetic papillopathy can present unilaterally or bilaterally, and is usually accompanied by signs of mild NPDR 
(though it may appear with any level of retinopathy or in the absence of retinopathy).1 Characteristic fundus 
findings include hyperemic optic disc swelling and telangiectatic vessels on or around the disc.2,3 Clinically 
significant macular edema is associated with 50-70% of eyes with diabetic papillopathy.1,2 Fundus fluorescein 
angiography (FA) will show focal or diffuse early hyperfluorescence on the disc with late leakage from telan-
giectatic vessels.2 
The pathogenesis of diabetic papillopathy remains unclear, though it is likely due to diabetic microvascular 
changes. The literature suggests that the disc edema is caused by superficial, retinal vascular disturbance with 
transient leakage of fluid into and around the optic nerve head.1 Some studies suggest that the disc edema origi-
nates from deeper within the optic nerve head, due to some vascular compromise that disrupts axoplasmic flow.1 
Although the first report of diabetic papillopathy dates back to 1971, there is still much debate to whether it is 
its own entity, a manifestation of diabetic retinopathy, or a form of anterior ischemic optic neuropathy (AION).1-5 
Metabolic control may also contribute to the development of diabetic papillopathy as it was found that there is 
a marked association between diabetic papillopathy and patients with a recent drastic reduction of HbA1c and 
small cup-to-disc ratios.2,4,6,11 Therefore, an HbA1c reduction of no more than -1.0% per quarter year is recom-
mended.4 In this case, the patient’s HbA1c levels had decreased by 1.5% in the month of presentation compared to 
the level recorded 3 months previously. 
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Grading optic disc edema
Optic disc edema can be graded qualitatively using the Modified Frisén Scale (MFS) or quantitatively using OCT.12 
The MFS uses key characteristics to assign a grade from 0 (normal optic disc) to 5 (severe edema), as indicated in 
Table 3.12 Fundus photographs are helpful when using the MFS. The MFS is better suited for categorizing higher-
grade edema and observing key features, while OCT is superior for lower-grade edema where subtle changes in the 
optic nerve are more difficult to discern.12 Additionally, the OCT RNFL thickness-processing algorithm often fails 
with higher-grade edema.12 The mean RNFL thickness on the Spectralis SD-OCT in the average population is 97.3 ± 
9.6 µm.13 At his initial presentation, the patient had grade 4 edema and grade 2 edema on the MFS, and a global RNFL 
thickness value of 244 µm for the right eye and 210 µm for the left eye. MFS was initially better suited for monitoring 
due to possible OCT RNFL algorithm failure with higher disc edema. 
Combined use of the MFS, fundus photographs, and OCT provides the best documentation to evaluate the overall 
clinical course of optic disc edema. 
Differential Diagnosis 
Since diabetic papillopathy is a diagnosis of exclusion, it is critical to rule out other possible causes such as AION, 
optic neuritis, and increased intracranial pressure from space-occupying lesions, infection, and inflammation.4 Pa-
tients with AION typically present with profound and sudden vision loss with a dense altitudinal visual field defect.2 
Optic neuritis is usually associated with ocular pain, dyschromatopsia, and visual field loss.1 Increased intracranial 
pressure from space-occupying lesions, infection, or inflammation can be excluded with cranial imaging (MRI, 
MRV CT), CSF studies and blood work. Idiopathic intracranial hypertension will present with increased opening 
pressure on LP and is often associated with headaches, diplopia, and malaise.7 MRI and CT can help detect space-
occupying lesions and MRV can help detect venous sinus thrombosis.14 There is a wide variety of infectious causes 
such as sarcoidosis, trichinosis, and toxoplasmosis.15 Infectious etiologies can be confirmed with laboratory testing 
such as CBC, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), polymerase chain reaction (PCR), 
and serological testing.16 Inflammation, such as in meningitis, can increase ICP by reducing CSF reabsorption.15 
Pseudopapilledema is the anomalous elevation of the optic disc due to drusen and can be diagnosed with a B-scan 
or fundus autofluorescence (FAF) of the optic nerve.17 Certain medications can also cause disc edema such as estro-
gens, tetracyclines, corticosteroids, and vitamin A.18 
Treatment
Diabetic papillopathy is often monitored without intervention due to its self-resolving nature and benign course.8 
Resolution can range from 3-12 months after initial presentation.3 Patients may have mild pallor of the optic discs 
upon resolution in cases of prolonged disc edema.19 The degree of edema has not been found to correlate with the 
initial acuity or visual outcome.19 
In cases of vision loss, anti-vascular endothelial growth factor (anti-VEGF) injections may be beneficial.8,9 Eyes 
injected with intravitreal bevacizumab showed a marked regression of disc edema and improvement in visual acu-
ities at the 2-week follow-up.8,9 However, further studies will be needed to prove its efficacy and safety in diabetic 
papillopathy. 
CONCLUSION
This case reports discusses the diagnosis and management of a patient presenting with characteristic findings of 
bilateral diabetic papillopathy; i.e., hyperemic disc edema and unremarkable findings on neurological testing, cra-
nial imaging, intracranial pressure, serology, and cerebral spinal fluid composition. The worldwide prevalence of 
diabetes has grown rapidly over the last few decades, and it is imperative for eye care providers to be familiar with 
some of the less common ocular complications of diabetes, including diabetic papillopathy. Furthermore, it is criti-
cal to differentiate diabetic papillopathy, a benign, self-limiting condition, from more life-threatening conditions 
that can cause optic disc edema. l
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